Correlation Between Clinical Course and Quantitative Analysis of the Ischemia Related Artery in Patients with Unstable Angina Pectoris, Refractory to Medical Treatment. Results of Two Randomized Trials. The European Cooperative Study Group

Overview

Journal Int J Card Imaging

Specialties Cardiology & Vascular Diseases
Radiology

Date 1994 Sep 1

PMID 7876657

Authors

M J van den Brand

A van Miltenburg

M J de Boer

L R van der Wieken

P J de Feyter

M L Simoons

Affiliations

Soon will be listed here.

Abstract

Patients with unstable angina, refractory to intensive medical therapy, are at high risk for developing thrombotic complications, such as recurrent ischemia, myocardial infarction and coronary occlusion during coronary angioplasty. As both platelet aggregation and/or thrombus formation play an important role in this ongoing ischemic process, a monoclonal platelet GPIIb/IIIa receptor antibody (c7E3) or thrombolytic therapy (alteplase) might be able to modify the clinical course and underlying coronary lesion morphology. To evaluate whether alteplase or c7E3 could influence the incidence of complications, we randomized 36 and 60 patients, respectively to alteplase or placebo, or c7E3 or placebo. All patients exhibited dynamic ECG changes and recurrent pain attacks, despite maximal tolerated medical therapy. Patients were randomized in both studies after initial angiography had demonstrated a culprit lesion amenable for angioplasty. After study drug infusion quantitative angiography was repeated and angioplasty performed. Recurrent ischemia during study drug infusion occurred in 5, 6, 9 and 16 patients from the alteplase, placebo, c7E3 and placebo group, respectively. Major events defined as death, myocardial infarction or urgent intervention occurred in 7, 3, 1 and 7 patients, respectively. Two patients died: one in the alteplase group and one in the placebo group from the c7E3 study. The first patient due to retroperitoneal hemorrhage, the second as a result of recurrent infarction. Qualitative angiography showed resolution of clots in the c7E3 group only, while the same group of patients showed in 20% an improvement in TIMI flow grade, without deterioration in any patient from this group.(ABSTRACT TRUNCATED AT 250 WORDS)

References

Verstraete M, BLEIFELD W, Brower R, Charbonnier B, Collen D, De Bono D . Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet. 1985; 2(8462):965-9. DOI: 10.1016/s0140-6736(85)90523-9. View

Waters D, Lam J . Is thrombolytic therapy striking out in unstable angina?. Circulation. 1992; 86(5):1642-4. DOI: 10.1161/01.cir.86.5.1642. View

van den Brand M, van Zijl A, Geuskens R, de Feyter P, Serruys P, Simoons M . Tissue plasminogen activator in refractory unstable angina. A randomized double-blind placebo-controlled trial in patients with refractory unstable angina and subsequent angioplasty. Eur Heart J. 1991; 12(11):1208-14. DOI: 10.1093/eurheartj/12.11.1208. View

de Feyter P, Suryapranata H, Serruys P, Beatt K, van Domburg R, van den Brand M . Coronary angioplasty for unstable angina: immediate and late results in 200 consecutive patients with identification of risk factors for unfavorable early and late outcome. J Am Coll Cardiol. 1988; 12(2):324-33. DOI: 10.1016/0735-1097(88)90401-9. View

Chesebro J, Knatterud G, Roberts R, Borer J, Cohen L, Dalen J . Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987; 76(1):142-54. DOI: 10.1161/01.cir.76.1.142. View

Topol E, Nicklas J, Kander N, Walton J, ELLIS S, Gorman L . Coronary revascularization after intravenous tissue plasminogen activator for unstable angina pectoris: results of a randomized, double-blind, placebo-controlled trial. Am J Cardiol. 1988; 62(7):368-71. DOI: 10.1016/0002-9149(88)90960-5. View

Schreiber T, Rizik D, White C, Sharma G, Cowley M, Macina G . Randomized trial of thrombolysis versus heparin in unstable angina. Circulation. 1992; 86(5):1407-14. DOI: 10.1161/01.cir.86.5.1407. View

Lawrence J, SHEPHERD J, Bone I, Rogen A, FULTON W . Fibrinolytic therapy in unstable angina pectoris. A controlled clinical trial. Thromb Res. 1980; 17(6):767-77. DOI: 10.1016/0049-3848(80)90242-x. View

Reiber J, Serruys P, Kooijman C, Wijns W, Slager C, Gerbrands J . Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation. 1985; 71(2):280-8. DOI: 10.1161/01.cir.71.2.280. View

10.

Fitzgerald D, Wright F, FitzGerald G . Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res. 1989; 65(1):83-94. DOI: 10.1161/01.res.65.1.83. View

11.

WILLIAMS D, Topol E, Califf R, Roberts R, Mancini G, Joelson J . Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial. Circulation. 1990; 82(2):376-83. DOI: 10.1161/01.cir.82.2.376. View

12.

Ardissino D, Barberis P, De Servi S, Mussini A, Rolla A, Visani L . Recombinant tissue-type plasminogen activator followed by heparin compared with heparin alone for refractory unstable angina pectoris. Am J Cardiol. 1990; 66(12):910-4. DOI: 10.1016/0002-9149(90)90924-p. View

13.

Eisenberg P, Sherman L, Jaffe A . Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol. 1987; 10(3):527-9. DOI: 10.1016/s0735-1097(87)80194-8. View

14.

Leinbach R . Thrombolysis in unstable angina. Circulation. 1992; 85(1):376-7. DOI: 10.1161/01.cir.85.1.376. View

15.

Braunwald E . Unstable angina. A classification. Circulation. 1989; 80(2):410-4. DOI: 10.1161/01.cir.80.2.410. View

16.

Golino P, Ashton J, MCNATT J, Buja L, Willerson J . Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation. 1988; 77(3):678-84. DOI: 10.1161/01.cir.77.3.678. View

17.

Sansa M, Cernigliaro C, Campi A, Simonetti I . Effects of urokinase and heparin on minimal cross-sectional area of the culprit narrowing in unstable angina pectoris. Am J Cardiol. 1991; 68(5):451-6. DOI: 10.1016/0002-9149(91)90777-i. View

18.

Crawford D, Brooks S, Selzer R, Barndt Jr R, Beckenbach E, Blankenhorn D . Computer densitometry for angiographic assessment of arterial cholesterol content and gross pathology in human atherosclerosis. J Lab Clin Med. 1977; 89(2):378-92. View

19.

NERI SERNERI G, Gensini G, Poggesi L, Trotta F, Modesti P, Boddi M . Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet. 1990; 335(8690):615-8. DOI: 10.1016/0140-6736(90)90407-v. View

20.

Goldman B, Katz A, Christakis G, Weisel R . Determinants of risk for coronary artery bypass grafting in stable and unstable angina pectoris. Can J Surg. 1985; 28(6):505-8. View